The Food and Drug Administration on Monday approved Sanofi and Regeneron Pharmaceutical's biologic drug Kevzara.
Kevzara is intended to treat patients with moderate to severe rheumatoid arthritis who do not respond to other treatments. The drug is administered via a subcutaneous injection once every two weeks.
Kevzara will cost $39,000 annually for the 150 milligram and 200 milligram doses. Sanofi and Regneron said this figure marks a 30 percent decrease from the cost of two the rival drugs on the market.
More articles on supply chain:
McKesson 2017 revenue up 4%: 5 things to know
What Trump's budget proposal means for FDA funding
Baking soda shortage forces hospitals to postpone surgeries, treatments